14 total views, 1 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis Howard Lake | 29 April 2001 | News AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis China’s first charity Web site The first charity Web site in China has been launched by the China Charity Federation. The first charity Web site in China has been launched by the China Charity Federation. The site features charity information, handles online donations and is developing a database of charity volunteers.Find out more from the People’s Daily and visit the China Charity Federation. Advertisement About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving.
Oxford had a mixed day at the Henley Boat Races, which take place the day before the Men’s Boat Race. The Dark Blues won every race except for the eagerly anticipated Women’s Blue boat race. Oxford’s Women lost out to a powerful Cambridge crew by two and a third lengths, but there were victories for Men and Women’s Lightweight Blues as well as Osiris, the Women’s reserve crew, and Nepthys, the Lightweight Men’s reserves.The Women Blues followed a risky strategy which reflected their status as underdogs. Having finished well below Cambridge at the Women’s Head race three weeks previously, Oxford clearly felt they had to rattle Cambridge in the early stages of the contest to win. They blasted off the start rating three strokes per minute higher than the Tabs through the first kilometre of the course to inch into a length lead.The Cambridge crew, however, kept their composure. Rowing a much more efficient rhythm, they stayed in touch while Oxford charged and exhausted energy. As the race reached halfway, Cambridge pushed hard, cancelling out Oxford’s advantage, before powering into the lead. Oxford had already given too much to respond, and were left clinging on desperately as the Light Blue boat gradually extended their lead to the finish.President Nicola Fawcett was proud of her team, saying, “the girls rowed everything well. They front-loaded the race to put Cambridge under pressure, but Cambridge’s faster cruising speed paid off”. Fawcett’s disappointment was partly tempered by Osiris’ victory, where Oxford battled to a small lead in the first 1000m before stretching out to a one length win.The Lightweight races, however, belonged to Oxford. The Lightweight Blues crushed Cambridge by three lengths, while Nepthys was even more dominant, winning by four lengths. President James Gillies commented, “Our squad has been awesome, our coaching excellent and I think the results reflect this.” The Women Lightweights provided the race of the day, protecting a tiny lead against successive Cambridge pushes. Blades clashed all the way down the course as both coxes attempted to eek out a winning advantage and the race was still tight in the closing stages until the Dark Blues pushed on to win by a single length. President Claire Weldon was “delighted and relieved to win such a close race”.ARCHIVE: 0th week TT 2005
A major, multi-institutional study based at Harvard-affiliated Massachusetts General Hospital (MGH) has identified a promising treatment strategy for Huntington’s disease (HD).The team’s identification of a novel compound, MIND4, appears to protect against neurodegeneration in cellular and animal models of HD by means of two separate mechanisms — inhibiting a regulatory enzyme of the nervous system (SIRT2), and stimulating activity of the NRF2 pathway, which regulates the expression of protective, antioxidant proteins. The report will be published online in the journal Cell Chemical Biology.“Based on numerous studies, it has become evident that the pathologies of neurodegenerative diseases, including Huntington’s disease, are very complex, so targeting multiple pathways may help us achieve maximum therapeutic benefit,” said Aleksey Kazantsev, who led the study as an investigator at the MassGeneral Institute for Neurodegenerative Disease (MIND). “The lead compound identified in the current study has two distinct mechanisms, both of which are shown to be potentially neuroprotective and which we expect will have synergistic benefits.”Previous work from Kazantsev’s MIND team identified SIRT2 as a promising treatment target for Huntington’s as well as for Parkinson’s disease. Building on those findings, he and his collaborators from 12 research institutions in five countries began searching for a scaffold — a group of molecules with similar chemical structures — that could be the basis of more potent and selective SIRT2 inhibitors. Starting with the most powerful SIRT2-inhibiting compound they identified, which they called MIND4, they assembled a group of structurally similar compounds with varying levels of effectiveness.In investigating how MIND4 acted to inhibit SIRT2, the researchers were surprised to find that the top seven pathways activated by treatment with MIND4 were related to the oxidative stress response mediated by NRF2. Additional experiments indicated that activation of NRF2-mediated pathways did not depend on SIRT2 inhibition.“Finding that MIND4’s SIRT2 and NRF2 activities are independent of each other is a critical step for further drug development, which indicates that work to improve the potency of each activity should proceed separately,” said Kazantsev. “We still don’t know whether the neuroprotective results we observed in this study depend more on one activity or the other, but since MIND4, which produces both activities, was a better protectant than [a MIND4 derivative] which only activates NRF2, I speculate that both activities will be necessary.”He added, “MIND4 is a great starting template for drug development, and we have promising preliminary results in two mouse models. We also need to optimize the pharmacology to meet FDA requirements for a version we can test in human patients. Right now, we expect to have results regarding the mechanism behind NRF2 activation ready for submission soon.” Kazantsev recently joined the Cambridge, Mass.-based startup company Effective Therapeutics, LLC, but continues to collaborate with his colleagues at MGH and other institutions.Anne B. Young, former MGH chief of neurology and founder of MIND as well as Effective Therapeutics, said, “These multidisciplinary studies highlight new pathways that can be targeted for HD therapy but also very likely for other neurodegenerative diseases, too.”A pdf of the study is available here.
Wellington Police notes for Wednesday, December 9, 2015â€¢12:32 p.m. Officers investigated a theft of a vehicle in the 1100 block S. C, Wellington.â€¢3:22 p.m. Officers investigated identity theft by known suspect in the 200 block E. Kansas, Wellington.â€¢6:32 p.m. Officers took a report of child custody dispute in the 400 block N. Circle, Wellington.â€¢10:58 p.m. Alvin J. Cox, 53, Sacramento, Calif. was issued a notice to appear for expired registration, no proof of insurance and speeding 42 mph in a 30 mph zone.
Sosa hit 66 home runs in 1998 and then 63 in 1999 — more in a two-year stretch than Babe Ruth, Barry Bonds or Hank Aaron ever managed.His fall from grace in subsequent years — related to allegations he used performance enhancing drugs — has kept him separated from the Cubs and mostly out of the public eye.Sosa is back in the spotlight this weekend, though, as ESPN relives the peak of his career Sunday night in “Long Gone Summer.” Sammy Sosa then, and Sammy Sosa now, don’t look like the same human being. They don’t even look related to each other. pic.twitter.com/bp9QxysV3y— L E F T, PhD ⚫️ (@LeftSentThis) July 13, 2017″It’s a bleaching cream that I apply before going to bed and whitens my skin some,” Sosa said in a 2009 interview with Univision after a photo was taken at the Grammy Latino Awards, a first look at Sosa’s lighter complexion.”What happened was that I had been using the cream for a long time and that, combined with the bright TV lights, made my face look whiter than it really is. I don’t think I look like Michael Jackson,” he said then.Sosa, now 51, has given only a handful of interviews since his retirement from MLB in 2004. In a 2018 interview with NBC Sports Chicago , he said he is healthy and denounced the criticism he’s received amid rumors of skin bleaching. “Those people they sometimes criticize me, they don’t know me, they don’t put food on my table and they don’t pay my bills,” he said.Sosa has maintained his lightened skin tone was an unintended side effect of using the cream and unrelated to race: “I’m not a racist, I live my life happily.” Sammy Sosa no longer looks like he did during the 1990s when he battled Mark McGwire for home run supremacy. His change in appearance has been the subject of questions for a while, and the scrutiny has increased this weekend in response to ESPN releasing a documentary about his prolific 1998 summer on the baseball diamond.Sosa, born in the Dominican Republic, has a much whiter complexion than he did during his MLB career. He’s said in the past that his skin carries a different appearance now because of a cream he uses that includes bleach, a practice that has garnered criticism and jokes on social media.